Skip to main content
SpringerLink
Log in

Inhibition of Dendritic Cell Generation and Function by Serum from Prostate Cancer Patients: Correlation with Serum-Free PSA

  • Conference paper
Book cover Immune-Mediated Diseases

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 601))

Abstract

Tumor produces a number of immunosuppressive factors that block maturation of dendritic cells (DCs). Here, we demonstrated that endogenous factors presented in the serum of patients with prostate cancer (CaP) inhibited the generation of functionally active DCs from CD14+ monocytes in vitro. We have shown a significant inhibitory potential of serum obtained from patients with CaP and benign prostate hyperplasia benign prostatic hyperplasia (BPH) when compared with serum from healthy volunteers. As assessed by flow cytometry, expression of CD83, CD86, and CD40 molecules was strongly inhibited by CaP and BPH serum. In addition, these DCs were weak stimulators of allogeneic T cell proliferation when compared with DCs produced in the presence of healthy volunteer serum. Statistical analysis of the results revealed a positive relationship between the inhibition of expression of DC markers CD83 and CD80 and the levels of serum-free prostate-specific antigen (PSA). These data suggest that the DC system may be impaired in CaP patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aalamian, M., Pirtskhalaishvili, G., Nunez, A., Esche, C., Shurin, G.V., Huland, E., Huland, H. and Shurin, M.R. (2001) Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46, 68–75.

    Article  PubMed  CAS  Google Scholar 

  • Aalamian, M., Tourkova, I.L., Chatta, G.S., Lilja, H., Huland, E., Huland, H., Shurin, G.V. and Shurin, M.R. (2003) Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J. Urol. 170, 2026–2030.

    Article  PubMed  CAS  Google Scholar 

  • Armstrong, T.D., Pulaski, B.A. and Ostrand-Rosenberg, S. (1998) Tumor antigen presentation: changing the rules. Cancer Immunol. Immunother. 46, 70–74.

    Article  PubMed  CAS  Google Scholar 

  • Arya, M., Bott, S.R., Shergill, I.S., Ahmed, H.U., Williamson, M. and Patel, H.R. (2006) The metastatic cascade in prostate cancer. Surg. Oncol. 23, 77–83.

    Google Scholar 

  • Becker, Y. (1992) Anticancer role of dendritic cells (DC) in human and experimental cancers – a review. Anticancer Res. 12, 511–520.

    PubMed  CAS  Google Scholar 

  • Catalona, W.J., Partin, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., Patel, A., Richie, J.P., deKernion, J.B., Walsh, P.C., Scardino, P.T., Lange, P.H., Subong, E.N., Parson, R.E., Gasior, G.H., Loveland, K.G. and Southwick, P.C. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542–1547.

    Article  PubMed  CAS  Google Scholar 

  • Christensson, A., Bjork, T., Nilsson, O., Dahlen, U., Matikainen, M.T., Cockett, A.T., Abrahamsson, P.A. and Lilja, H. (1993) Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 150, 100–105.

    PubMed  CAS  Google Scholar 

  • Christensson, A., Laurell, C.B. and Lilja, H. (1990) Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194, 755–763.

    Article  PubMed  CAS  Google Scholar 

  • Colaco, C.A. (1999a) DC-based cancer immunotherapy: the sequel. Immunol. Today 20, 197–198.

    Article  PubMed  CAS  Google Scholar 

  • Colaco, C.A. (1999b) Why are dendritic cells central to cancer immunotherapy? Mol. Med. Today 5, 14–17.

    Article  PubMed  CAS  Google Scholar 

  • Comuzzi, B. and Sadar, M.D. (2006) Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cell Sci. 3, 61–81.

    Google Scholar 

  • Diamandis, E.P. and Yu, H. (1997) Nonprostatic sources of prostate-specific antigen. Urol. Clin. North. Am. 24, 275–282.

    Article  PubMed  CAS  Google Scholar 

  • Elabbady, A.A. and Khedr, M.M. (2006) Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml. Int. Urol. Nephrol. 38, 553–557.

    Article  PubMed  CAS  Google Scholar 

  • Frassica, F.J., Gitelis, S. and Sim, F.H. (1992) Metastatic bone disease: general principles, pathophysiology, evaluation, and biopsy. Instr. Course Lect. 41, 293–300.

    PubMed  CAS  Google Scholar 

  • Hall, C.L., Bafico, A., Dai, J., Aaronson, S.A. and Keller, E.T. (2005) Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 65, 7554–7560.

    PubMed  CAS  Google Scholar 

  • Harris, D.T., Matyas, G.R., Gomella, L.G., Talor, E., Winship, M.D., Spitler, L.E. and Mastrangelo, M.J. (1999) Immunologic approaches to the treatment of prostate cancer. Semin. Oncol. 26, 439–447.

    PubMed  CAS  Google Scholar 

  • Healy, C.G., Simons, J.W., Carducci, M.A., DeWeese, T.L., Bartkowski, M., Tong, K.P. and Bolton, W.E. (1998) Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32, 109–119.

    Article  PubMed  CAS  Google Scholar 

  • Herr, H.W. (1980) Suppressor cells in immunodepressed bladder and prostate cancer patients. J. Urol. 123, 635–639.

    PubMed  CAS  Google Scholar 

  • Huang, A.Y.C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H. (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961–965.

    Article  PubMed  CAS  Google Scholar 

  • Ivshina, A.V., Zhumagazin Zh, D., Zabotina, T.N., Matveev, B.P. and Kadagidze, Z.G. (1995) Effect of the spread of the process and treatment on the phenotype of peripheral blood lymphocytes in patients with prostatic cancer. Urologiia. i. Nefrologiia 9, 36–38.

    Google Scholar 

  • Jung, K., Brux, B., Lein, M., Rudolph, B., Kristiansen, G., Hauptmann, S., Schnorr, D., Loening, S.A. and Sinha, P. (2000) Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin. Chem. 46, 47–54.

    PubMed  CAS  Google Scholar 

  • Landis, S.H., Murray, T., Bolden, S. and Wingo, P.A. (1999) Cancer statistics, 1999. CA Cancer J. Clin. 49, 8–31.

    Article  PubMed  CAS  Google Scholar 

  • Li, N., Qin, H., Li, X., Zhou, C., Wang, D., Ma, W., Lin, C., Zhang, Y., Wang, S. and Zhang, S. (2006) Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. J. Clin. Immunol. 27, 117–130.

    Article  PubMed  CAS  Google Scholar 

  • Lilja, H. (1993) Structure, function, and regulation of the enzyme activity of prostate- specific antigen. World J. Urol. 11, 188–191.

    Article  PubMed  CAS  Google Scholar 

  • Lotze, M.T. (1997) Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer [editorial; comment]. Ann. Surg. 226, 1–5.

    Article  PubMed  CAS  Google Scholar 

  • McGregor, A.R., Moore, M.L., Bailey, R.R., Robson, R.A. and Lynn, K.L. (1990) Disseminated prostatic carcinoma presenting with acute interstitial nephritis and microangiopathic haemolytic anaemia. Aust. N. Z. J. Med. 20, 170–172.

    PubMed  CAS  Google Scholar 

  • Mohamedali, K.A., Poblenz, A.T., Sikes, C.R., Navone, N.M., Thorpe, P.E., Darnay, B.G. and Rosenblum, M.G. (2006) Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 66, 10919–10928.

    Article  PubMed  CAS  Google Scholar 

  • Oesterling, J.E. (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145, 907–923.

    PubMed  CAS  Google Scholar 

  • Polascik, T.J., Oesterling, J.E. and Partin, A.W. (1999) Prostate specific antigen: a decade of discovery–what we have learned and where we are going. J. Urol. 162, 293–306.

    Article  PubMed  CAS  Google Scholar 

  • Ragde, H., Cavanagh, W.A. and Tjoa, B.A. (2004) Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J. Urol. 172, 2532–2538.

    Article  PubMed  Google Scholar 

  • Salgaller, M.L., Lodge, P.A., McLean, J.G., Tjoa, B.A., Loftus, D.J., Ragde, H., Kenny, G.M., Rogers, M., Boynton, A.L. and Murphy, G.P. (1998) Report of immune monitoring of prostate cancer patients undergoing T cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen. Prostate 35, 144–151.

    Article  PubMed  CAS  Google Scholar 

  • Shamdas, G.J., Ahmann, F.R., Matzner, M.B. and Ritchie, J.M. (1993) Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 71, 3594–3600.

    CAS  Google Scholar 

  • Shurin, G.V., Aalamian, M., Pirtskhalaishvili, G., Bykovskaia, S., Huland, E., Huland, H. and Shurin, M.R. (2001) Human prostate cancer blocks the generation of endritic cells from CD34+ hematopoietic progenitors. Eur. Urol. 39 (suppl), 37–40.

    Article  PubMed  Google Scholar 

  • Shurin, M.R. (1996) Dendritic cells presenting tumor antigen. Cancer Immunol. Immunother. 43, 158–164.

    Article  PubMed  CAS  Google Scholar 

  • Simons, J.W., Mikhak, B., Chang, J.F., DeMarzo, A.M., Carducci, M.A., Lim, M., Weber, C.E., Baccala, A.A., Goemann, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H.B., Piantadosi, S., Marshall, F.F. and Nelson, W.G. (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160–5168.

    PubMed  CAS  Google Scholar 

  • Slovin, S.F., Kelly, W.K. and Scher, H.I. (1998) Immunological approaches for the treatment of prostate cancer. Semin. Urol. Oncol. 16, 53–59.

    PubMed  CAS  Google Scholar 

  • Speiser, D.E., Miranda, R., Zakarian, A., Bachmann, M.F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R.M. and Ohashi, P.S. (1997) Self antigens expressed by soild tumors do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J. Exp. Med. 186, 645–653.

    Article  PubMed  CAS  Google Scholar 

  • Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S. and Redwine, E. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916.

    Article  PubMed  CAS  Google Scholar 

  • Stephan, C., Jung, K., Lein, M., Sinha, P., Schnorr, D. and Loening, S.A. (2000) Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9, 1133–1147.

    PubMed  CAS  Google Scholar 

  • Troy, A., Davidson, P., Atkinson, C. and Hart, D. (1998) Phenotypic characterization of the dendritic cell infiltrate in prostate cancer. J. Urol. 160, 214–219.

    Article  PubMed  CAS  Google Scholar 

  • Troy, A., Davidson, P., Atkinson, C. and Hart, D. (1999) Renal cell carcinoma and prostate cancer inhibit dendritic cell activation. Aust. N. Z. J. Surg. 69, A111–A112.

    Google Scholar 

  • Williams, S.A., Singh, P., Isaacs, J.T. and Denmeade, S.R. (2006) Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 67, 312–329.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA

    Maryam Aalamian-Matheis

  2. Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

    Gurkamal S. Chatta

  3. Department of Pathology and Immunology, University of Pittsburgh, Pittsburgh, PA, USA

    Michael R. Shurin

  4. Department of Urology, University Clinics Hamburg-Eppendorf, Hamburg, Germany

    Edith Huland & Hartwig Huland

  5. Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA

    Galina V. Shurin

Authors
  1. Maryam Aalamian-Matheis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gurkamal S. Chatta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael R. Shurin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edith Huland
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hartwig Huland
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Galina V. Shurin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Galina V. Shurin .

Editor information

Editors and Affiliations

  1. Division of Clinical Immunopathology, 5725 Children’s Hospital of Pittsburgh, Main Tower, 200 Lothrop Street, Pittsburgh, PA, 15213, USA

    Michael R. Shurin (Associate Professor of Pathology and Immunology, Associate Director) (Associate Professor of Pathology and Immunology, Associate Director)

  2. Institute for Continuing Medical Education, Russian Association of Pediatric Allergology and Immunology, Clinical and Research Center of Allergy and Immunology, Ostrovitianova St., Bldg. 6, Moscow, 117513, Russia

    Yuri S. Smolkin (Professor of Immunology, Vise-President, Director) (Professor of Immunology, Vise-President, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this paper

Cite this paper

Aalamian-Matheis, M., Chatta, G.S., Shurin, M.R., Huland, E., Huland, H., Shurin, G.V. (2007). Inhibition of Dendritic Cell Generation and Function by Serum from Prostate Cancer Patients: Correlation with Serum-Free PSA. In: Shurin, M.R., Smolkin, Y.S. (eds) Immune-Mediated Diseases. Advances in Experimental Medicine and Biology, vol 601. Springer, New York, NY. https://doi.org/10.1007/978-0-387-72005-0_18

Download citation

Publish with us

Policies and ethics

Search

Navigation